New data show VEGF bispecifics could compete with Summit, Akeso drug

Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb; and PF'4404, from the partnership between Pfizer and 3SBio.

Raccontata daendpoints.news